Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hansoh Signs $218 Million Agreement with NiKang for Oncology Asset

publication date: May 3, 2022

Shanghai Hansoh Pharma announced a $218 million agreement to acquire Greater China rights for a small molecule oncology candidate developed by NiKang Pharma of Delaware. NiKang is currently conducting a US Phase I/II dose escalation and expansion trial of NKT2152, a small molecule drug that inhibits HIF2α, in patients with clear cell renal cell carcinoma. Hansoh will pay $15 million upfront and up to $203 million in milestone payments, plus royalties. It’s the second partnership between the two companies: two years ago, Hansoh in-licensed greater China rights to a small molecule anti-viral candidate from NiKang in a $100 million deal. More details....

Stock Symbol: (HK: 3692)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here